You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星医药AH股午後跌幅曾扩至7%-8% 调查复必泰疫苗产品包装瑕疵原因
阿思达克 03-24 14:22
复星医药(02196.HK)调查复必泰疫苗产品包装瑕疵原因,该股午後跌幅曾扩至7%低见31.75元,现造32.3元,跌5.4%,成交增至333万股;其A股(600196.SH)午後股价跌幅曾扩至逾8%低见36.67元人民币,现造37.65元人民币,跌5.8%,成交3,175万股。

复星医药公告指,昨晚接获BioNTech书面通知,BioNTech注意到其生产供应香港与澳门批号为210102的复必泰疫苗产品中存在少量西林瓶封盖有关瑕疵。为确保疫苗接种安全,BioNTech和集团已发起对该问题原因调查,并已通知港澳即日起暂停接种该批号复必泰疫苗,直至调查结束。此外,出於谨慎考虑,用於供应香港的批号为210104疫苗产品也将进行封存,直至另行通知。不过,截至本公告日,未有证据表明相关批次产品安全可能存在风险,具体情况以最终调查结果为准。该疫苗是次暂停使用并作封存,对於相关批次疫苗在香港、澳门的後续接种安排可能存在影响,具体以调查结果为准。不过,该疫苗是次暂停使用并作封存,预计不会对集团正常生产经营造成重大影响。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account